BioSpace News Archive

Biotech Bay

Iovance Biotherapeutics Announces 33-Month Follow Up Data for Lifileucel in Advanced Melanoma at ASCO 2021 Annual Meeting

Median Duration of Response (DOR) Not Reached at 33.1 Months of Median Study Follow Up in Cohort 2 in C-144-01 Study

June 6, 2021
·
8 min read
Drug Development

AnHeart and Innovent Releases Preliminary Results from the Phase II TRUST Trial of Taletrectinib in ROS1 Fusion Positive NSCLC at the ASCO 2021 Annual Meeting

AnHeart Therapeutics Co., Ltd together with Innovent Biologics, Inc., jointly announce a presentation of a scientific poster entitled “Preliminary results from TRUST: A phase II clinical study to investigate Taletrectinib in treating patients with ROS1 fusion positive non-small cell lung cancer ” which summarizes initial data from its ongoing trial of taletrectinib at the American Society of Clinical Oncology 2021 Annual Meeting.

June 6, 2021
·
8 min read
Drug Development

Innovent and AnHeart Release Preliminary Results from the Phase II TRUST Trial of Taletrectinib in ROS1 Fusion Positive NSCLC at the ASCO 2021 Annual Meeting

Innovent Biologics, Inc together with AnHeart Therapeutics Co., Ltd jointly announced a presentation of a scientific poster entitled “Preliminary results from TRUST: A phase II clinical study to investigate Taletrectinib in treating patients with ROS1 fusion positive non-small cell lung cancer " which summarizes initial data from its ongoing trial of taletrectinib at the American Society of Clinical Oncology 2021 Annual Meeting.

June 6, 2021
·
7 min read